First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease

INTRODUCTION: Aducanumab (BIIB037), a human monoclonal antibody selective for aggregated forms of amyloid beta, is being investigated as a disease-modifying treatment for Alzheimer's disease (AD). METHODS: This randomized, double-blind, placebo-controlled single ascending-dose study investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrero, James, Williams, Leslie, Stella, Heather, Leitermann, Kate, Mikulskis, Alvydas, O'Gorman, John, Sevigny, Jeff
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651340/
https://www.ncbi.nlm.nih.gov/pubmed/29067304
http://dx.doi.org/10.1016/j.trci.2016.06.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651340/
https://www.ncbi.nlm.nih.gov/pubmed/29067304
http://dx.doi.org/10.1016/j.trci.2016.06.002

Ejemplares similares